ITRN — Ituran Location and Control Ltd.

Ituran Location and Control Ltd. (NASDAQ: ITRN) — deep-value analysis, resumed in REFRESH regime

September 15, 2026 · reference price … (Monday 09/14/2026 close, yfinance) · market cap … on 19.78 mil. shares outstanding · reporting and trading currency: USD

Regime: REFRESH on the reference thesis of 08/23/2026 (rapoarte/deep/2026-08-23-deep-ITRN.md, verdict at the time: WATCH). The mechanical triage deep_delta.py of 09/13/2026 called for resumption for two reasons: an unclassifiable 6-K filing (09/09/2026) and a falsifier that remained unverifiable (revenue_growth_yoy, missing a quarter).

What I explicitly inherit, since no fact touching it has changed: the business and moat structure, the 2019–H1 2026 capital-allocation history, the 06/30/2025 → 06/30/2026 balance-sheet table, the entire O’Glove analysis across five tests (receivables/DSO, inventory/DIO, debt, discretionary expenses, Sloan accruals), the Thorndike grid, the FCF bridge, and the five valuation models as intrinsic values. Between 08/23/2026 and today no new quarter has appeared — the next report (Q3 2026) is scheduled for 11/11/2026 — so all financial figures remain those from the 6-K of 08/12/2026 and the FY2025 20-F.

What I re-derived in this resumption:

1. The new filing (6-K of 09/09/2026, the first multi-year contract for the Big Data platform) — sized and framed; it doesn’t move the DCF.
2. The broken falsifier — resolved, with the missing quarter derived from the filing, not guessed.
3. The organic growth / currency translation decomposition, done from scratch with quarterly average market exchange rates (ILS, BRL, MXN, ARS) and the exact geographic weights from the FY2025 20-F. This had been listed in the delta package as “remained unverified, only publishes in the April 2027 20-F.” It can be verified today, and the result changes a central figure of the reference thesis: organic growth isn’t ~11%, it’s ~6%.
4. Subscriber dynamics by channel and country, with average revenue per subscriber in local currency — the first independent confirmation of the “volume, not price” mechanism.
5. The state of the F-3ASR shelf at three and a half months since filing.
6. The MOS of all models, recalculated at today’s price; Monte Carlo rerun on the same assumptions.

Primary sources: FY2025 20-F (filed 04/23/2026, CIK 1337117), 6-K of 08/12/2026 (Q2 2026), 6-K of 09/09/2026 (+ Exhibit 99.1), F-3ASR of 05/28/2026, the complete 2026 EDGAR filing list (checked today), data-pack-ITRN-20260915.md, average exchange rates from daily market series.

Executive summary

The thesis remains that of August, but with one leg stronger and one leg weaker.

The business is unchanged and continues to be nearly ideal: 2,711,000 subscribers at June 30, 2026, 76% recurring revenue, gross margin …% and operating margin 22.7% in Q2 2026, ROE ~29…, zero financial debt, and … cash. Tangible capital employed is under … for ~… of after-tax operating profit — a return on tangible capital on the order of 90…. Nothing in the last three weeks’ filings touches this picture.

The stronger leg: I could finally measure how much of the growth is currency. The reference thesis estimated 8-9 points of translation out of the 19.7 points of H1 2026 growth, hence organic growth “on the order of 11%.” With the exact weights from the 20-F (Israel 54.8% of revenue, Brazil 22.9%, the rest 22.3%) and the real quarterly average rates (the shekel 3.5951 → 3.0366 versus the dollar between H1 2025 and H1 2026, i.e. … translation effect; the real …), the overall currency effect is +12.6 to +12.8 percentage points, not 8-9. H1 2026 organic growth is …, and Q2 2026 is +5.6…5.7%. Independent confirmation comes from subscribers: the base grew from 2,548,000 to 2,711,000 over four quarters, i.e. …. The two figures, obtained via completely separate paths, coincide. The g1 = 6% assumption in the DCF is no longer a prudent estimate — it’s the measured organic rate.

The weaker leg: the volume pace is decelerating. In 2025, the subscriber base grew 9.2% (2,409,000 → 2,630,000, 221,000 net additions). Over the trailing four quarters it grew 6.4% (163,000 net additions), and Q2 2026 brought 41,000 — an annualized pace of 164,000. Product revenue, the physical channel through which new subscribers enter, grew 8% YoY in Q2 in dollars, but with a translation effect of ~+14 points on its geographic mix, that means a decline of ~5% in local currency. The company’s only real engine — volume — is slowing exactly in the quarters where dollar reporting shows records.

The new filing (09/09/2026) is a small good-news item, not a thesis change. Ituran won its first multi-year commercial contract for the Big Data platform: a SaaS traffic-monitoring service for entities of the Israeli Ministry of Transport, for up to four years, total value over NIS 21 mil. (~…), of which only NIS 5 mil. (~…) in the first year is guaranteed. Against annualized revenue of ~…, that’s 0.4% of revenue. Even at a generous incremental margin of 80… on already-collected data, the contribution to operating profit is ~…, i.e. ~1.6% of estimated 2026 operating profit, or ~1.5% of the price capitalized at 10x. I’m not raising g1 for it and not putting it in the DCF. Its value is of another nature: it’s the first external proof that the data platform can be sold separately from subscriptions, after management had announced it in February as one of three growth initiatives (Big Data, IturanMob — shared-mobility rental, launched in the US, and monetizing carbon credits for electric-vehicle drivers).

Estimated value. The flow to the shareholder used in the valuation remains … — normalized FCFE, defined in the valuation chapter and untouched by the new filings. The five triangulated models, recalculated at … give a range from … (pessimistic DCF) to … (optimistic DCF), with the median at …. Monte Carlo over 20,000 scenarios (same assumptions: OE 65, g1 6%, r 10%, gt 2%, net cash −95) gives a median intrinsic value of … and a median MOS of ** …**, with … probability of undervaluation — but P25 is …, i.e. a quarter of scenarios are more than ten percent worse than the price paid.

Verdict: WATCH — unchanged, but with a sounder justification than in August. In August I said “expensive on three of five models, and the family has its whole package on the shelf.” Today I add something heavier: the business’s real growth rate is 6%, not 20%, and it’s decelerating, while the price bakes in …x profit and a re-rating from the historical median of 10.5x. The entry threshold remains …-40 (the EPV Greenwald zone). Anyone already holding the stock has no reason for an urgent sale: the regular 3.92% dividend pays for the wait, the balance sheet is debt-free, and the business isn’t breaking — it’s gotten expensive.